890 assets in Neoplasm

Therapeutic assets addressing Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
[68ga]ga-nota-t4 Neoplasm	RenJi Hospital	P2/3	CCC (48)
Acasunlimab Neoplasm	Genmab	P1/2	CCC (48)
Adapt-001 Neoplasm	EpicentRx, Inc.	P2	CCC (48)
al8326 Neoplasm	Advenchen Laboratories Nanjing Ltd.	P1/2	CCC (48)
Belvarafenib Neoplasm	Hoffmann-La Roche	P2	CCC (48)
bi 907828 Neoplasm	Boehringer Ingelheim	P1	CCC (48)
Bms-986504 Neoplasm	Bristol-Myers Squibb	P2	CCC (48)
bnt324 Neoplasm	DualityBio Inc.	P2	CCC (48)
bnt327 Neoplasm	DualityBio Inc.	P2	CCC (48)
Brigimadlin Neoplasm	Boehringer Ingelheim	P2	CCC (48)
Dapagliflozin Neoplasm	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	P2	CCC (48)
Daraxonrasib Neoplasm	Bristol-Myers Squibb	P2	CCC (48)
db-1305/bnt325 Neoplasm	DualityBio Inc.	P2	CCC (48)
db-1311 Neoplasm	DualityBio Inc.	P2	CCC (48)
Divarasib Neoplasm	Hoffmann-La Roche	P2	CCC (48)
Edotreotide Neoplasm	MedSIR	P2	CCC (48)
Eflapegrastim Neoplasm	Spectrum Pharmaceuticals, Inc	P2	CCC (48)
Eflornithine Neoplasm	Aminex Therapeutics, Inc.	P1/2	CCC (48)
Eribulin/Farletuzumab Antibody Drug Conjugate Neoplasm	Eisai Inc.	P1/2	CCC (48)
g207 Neoplasm	Pediatric Brain Tumor Consortium	P2	CCC (48)
GSK3377794 Neoplasm	USWM CT, LLC	P2	CCC (48)
hlx301 Neoplasm	Shanghai Henlius Biotech	P1/2	CCC (48)
Hmpl-453 Neoplasm	Hutchison Medipharma Limited	P1/2	CCC (48)
Hrs-7058 Neoplasm	Shandong Suncadia Medicine Co., Ltd.	P2	CCC (48)
iah0968 Neoplasm	SUNHO（China）BioPharmaceutical CO., Ltd.	P2/3	CCC (48)
Ifebemtinib Neoplasm	InxMed (Shanghai) Co., Ltd.	P1/2	CCC (48)
Loratadine Neoplasm	Val Adams	P2	CCC (48)
NKT2152 Neoplasm	NiKang Therapeutics, Inc.	P2	CCC (48)
Ondansetron Neoplasm	UNC Lineberger Comprehensive Cancer Center	P1	CCC (48)
pm1032 Neoplasm	Biotheus Inc.	P1/2	CCC (48)
Pumitamig Neoplasm	Bristol-Myers Squibb	P2	CCC (48)
Rain-32 Neoplasm	Rain Oncology Inc	P2	CCC (48)
Rezatapopt Neoplasm	PMV Pharmaceuticals, Inc	P1/2	CCC (48)
rp-001 Neoplasm	Recurv Pharma Inc	P1/2	CCC (48)
Selumetinib Neoplasm	Merck Sharp & Dohme LLC	P1	CCC (48)
Slc-3010 Neoplasm	Yonsei University	P2	CCC (48)
Telpegfilgrastim Neoplasm	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P2	CCC (48)
Utomilumab Neoplasm	Pfizer	P3	CCC (48)
Bio-106 Neoplasm	BiOneCure Therapeutics Inc.	P1/2	CC (47)
Elacestrant Neoplasm	Stemline Therapeutics, Inc.	P1/2	CC (47)
hx044 Neoplasm	Hanx Biopharmaceuticals (Wuhan) Co., Ltd.	P1/2	CC (47)
sar444200 Neoplasm	Sanofi	P1/2	CC (47)
Star0602 Neoplasm	Marengo Therapeutics, Inc.	P1/2	CC (47)
Tiragolumab Neoplasm	Hoffmann-La Roche	P2	CC (47)
tt-816 Neoplasm	Teon Therapeutics, Inc.	P1/2	CC (47)
xs005 Neoplasm	Dushu Lake Hospital Affiliated to Soochow University	P1/2	CC (47)
Anti-Pd-1 Monoclonal Antibody Sym021 Neoplasm	Institut de Recherches Internationales Servier	P1	CC (46)
Apalutamide Neoplasm	Helsinki University Central Hospital	P2	CC (46)
CD47/SIRPA-BLOCKING AGENT ALX148 Neoplasm	QuantumLeap Healthcare Collaborative	P1	CC (46)
Celecoxib Neoplasm	Emory University	P2	CC (46)

Showing 201 to 250 of 890 assets

PreviousPage 5 of 18Next